Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
HUGO Series 🌟
HUGO-GT™ (Humanized Genomic Ortholog)
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)
MouseAtlas Model Library
Flash Sales
Research Models
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
Cell Line Models
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
iPSC Cell Line Product Catalog
AAV Standard Product Catalog
Services
Preclinical Efficacy
Neuroscience
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Models
Human Immune System (HIS) Mouse Model
Metabolic & Cardiovascular Diseases
Anti-Obesity
Autoimmune & Inflammatory
Asthma
Genetically Engineered Animals
Knockout Mice
Transgenic Mice
Knockin Mice
Knockout Rats
Knockin Rats
Transgenic Rats
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Breeding & Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Modalities
Gene Therapy
AI-Powered AAV Discovery
Oligonucleotide Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell Cell Culture
About Us
Corporate Overview
Facility Overview
Animal Health & Welfare
Health Reports
Our Team
Our Partners
Careers
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Arhgdibem1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Arhgdibem1/Cya
Common Name
Arhgdib-KO
Product ID
S-KO-18912
Backgroud
C57BL/6JCya
Strain ID
KOCMP-11857-Arhgdib-B6J-VB
Status
Research and Development
When using this mouse strain in a publication, please cite “Arhgdib-KO Mouse (Catalog S-KO-18912) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Arhgdib-KO
Strain ID
KOCMP-11857-Arhgdib-B6J-VB
Gene Name
Arhgdib
Product ID
S-KO-18912
Gene Alias
D4, Gdid4, Ly-GDI
Background
C57BL/6JCya
NCBI ID
11857 (Mouse)
Modification
Conventional knockout
Chromosome
Chr 6 (Mouse)
Phenotype
MGI:101940
Datasheet
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000032344
NCBI Transcript ID
NM_007486
Target Region
Exon 2~3
Size of Effective Region
~2.1 kb
Overview of Gene Research
Arhgdib, also known as Rho guanosine diphosphate dissociation inhibitor 2 (RhoGDI2), is a negative regulator of the Rho guanosine triphosphate (RhoGTP)ases RhoA, Rac1, and Cdc42 [4]. It mainly functions in regulating the actin network in various cells and is involved in multiple biological processes [4].

In bladder cancer, KDM6A promotes the transcription of Arhgdib by demethylating histone H3 lysine di/trimethylation (H3K27me2/3), which in turn inhibits Rac1 and blocks metastasis [1]. In breast cancer, Arhgdib expression is significantly higher in cancer tissues compared to benign tissues, and its depletion decreases cancer cell proliferation, migration, and invasion [5]. In kidney transplantation, pre-transplant anti-Arhgdib antibodies are associated with long-term kidney graft loss, and Arhgdib gene expression in the kidney is related to allograft outcome [2,3]. In trophoblasts, PD-L1 enhances migration and invasion by upregulating Arhgdib via transcription factor PU.1 [6]. In bladder cancer, ATG7-mediated autophagy promotes Arhgdib mRNA stability, leading to cancer cell invasion [7].

In conclusion, Arhgdib plays a crucial role in multiple biological processes and diseases, especially in cancer metastasis and kidney transplantation outcomes. The research on Arhgdib using various models helps to understand its functions in different physiological and pathological conditions, providing potential targets for disease treatment.

References:
1. Liu, Lei, Cui, Jianfeng, Zhao, Yajing, Shi, Benkang, Zou, Yongxin. 2021. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1. In Molecular cancer, 20, 77. doi:10.1186/s12943-021-01369-9. https://pubmed.ncbi.nlm.nih.gov/34006303/
2. Kamburova, Elena G, Gruijters, Maartje L, Kardol-Hoefnagel, Tineke, Bemelman, Frederike J, Otten, Henny G. 2019. Antibodies against ARHGDIB are associated with long-term kidney graft loss. In American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 19, 3335-3344. doi:10.1111/ajt.15493. https://pubmed.ncbi.nlm.nih.gov/31194283/
3. Senev, Aleksandar, Otten, Henny G, Kamburova, Elena G, Emonds, Marie-Paule, Naesens, Maarten. . Antibodies Against ARHGDIB and ARHGDIB Gene Expression Associate With Kidney Allograft Outcome. In Transplantation, 104, 1462-1471. doi:10.1097/TP.0000000000003005. https://pubmed.ncbi.nlm.nih.gov/31651716/
4. Kardol-Hoefnagel, Tineke, van Logtestijn, Sofie A L M, Otten, Henny G. 2020. A Review on the Function and Regulation of ARHGDIB/RhoGDI2 Expression Including the Hypothetical Role of ARHGDIB/RhoGDI2 Autoantibodies in Kidney Transplantation. In Transplantation direct, 6, e548. doi:10.1097/TXD.0000000000000993. https://pubmed.ncbi.nlm.nih.gov/32548242/
5. Wang, Xiaonan, Bi, Xiaomin, Huang, Xing, Guo, Qianying, Wu, Zhengsheng. . Systematic investigation of biomarker-like role of ARHGDIB in breast cancer. In Cancer biomarkers : section A of Disease markers, 28, 101-110. doi:10.3233/CBM-190562. https://pubmed.ncbi.nlm.nih.gov/32176626/
6. Zhang, Ruonan, Jia, Linyan, Meng, Lulu, Duan, Tao, Wang, Kai. 2022. PD-L1 enhances migration and invasion of trophoblasts by upregulating ARHGDIB via transcription factor PU.1. In Cell death discovery, 8, 395. doi:10.1038/s41420-022-01171-6. https://pubmed.ncbi.nlm.nih.gov/36138021/
7. Zhu, Junlan, Tian, Zhongxian, Li, Yang, Huang, Haishan, Huang, Chuanshu. 2019. ATG7 Promotes Bladder Cancer Invasion via Autophagy-Mediated Increased ARHGDIB mRNA Stability. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 6, 1801927. doi:10.1002/advs.201801927. https://pubmed.ncbi.nlm.nih.gov/31016112/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Models
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)HUGO-GT™ (Humanized Genomic Ortholog)MouseAtlas Model LibraryResearch Models
Services
NeuroscienceOphthalmologyOncologyMetabolic & Cardiovascular DiseasesAutoimmune & Inflammatory
About Us
Corporate OverviewFacility OverviewAnimal Health & WelfareHealth ReportsOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research